Evaluation of the effectiveness of Curcumin in the improving patients with autoimmune hepatitis
Phase 1
Recruiting
- Conditions
- Autoimmune hepatitis.Autoimmune hepatitisK75.4
- Registration Number
- IRCT20221112056476N1
- Lead Sponsor
- Zahedan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 68
Inclusion Criteria
Age range from 18 to 50 years
Suffering from autoimmune hepatitis based on diagnostic criteria (abnormalities of AST and ALT levels, hypergammaglobulinemia and increased serum IgG levels), positive serological findings (SMA, ANA and anti-LKM1) and histological findings and confirmed by an adult gastroenterologist
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Curcumin anti-inflammatory immunomodulatory mechanisms autoimmune hepatitis NF-kB TNF-alpha pathways
Comparative efficacy Curcumin versus azathioprine corticosteroids standard therapy autoimmune hepatitis
Biomarkers ALT AST IgG predicting treatment response Curcumin autoimmune hepatitis patients
Safety profile tolerability adverse events Curcumin supplementation liver disease autoimmune hepatitis
Alternative natural compounds therapeutic potential autoimmune hepatitis silymarin antioxidants immunomodulators